InnoSer News
InnoSer and Inficure Bio enter partnership to increase accessibility of translational liver inflammation & fibrosis mouse model
October 27th Diepenbeek, Belgium and Umeà, Sweden - InnoSer and Inficure Bio are announcing a strategic partnership to offer Inficure Bio’s spontaneous liver inflammation & fibrosis mouse model (NIF mouse) as part of InnoSer’s expanding cardiometabolic...
InnoSer expands preclinical cancer readout capabilities through acquisition of new imagers.
Getting closer to understanding cancer through the adoption of technological advancements is crucial in providing deeper insights for our customers. By building robust and reliable dossiers for promising drug candidates moving into clinical trials, we can help our...
Discussing innovation and the PDX/O platform at SINERGIA Summer School
We strive to stay at the forefront of biotechnological developments and to constantly incorporate innovation in our offerings - this is essential to be able to develop more reliable drug development platforms and avoid high drug attrition rates. Study director...
Facility management and preclinical services discussed at the FELASA Congress
Animal testing has played a critical role in the development of drugs, enabling us to ultimately obtain data which serves as a foundation to be able to deliver safe and effective drugs to patients. We are an AAALAC accredited organization committed to the 3Rs, by...
Get to know our preclinical drug development services at Knowledge for growth
We are constantly looking for opportunities to exchange and develop ideas, as they are the foundation for scientific advances and innovation. In addition to our collaboration with academic and commercial partners, attending conferences such as Knowledge for Growth...
Showcasing InnoSer’s in vivo portfolio at the Dutch life sciences conference
We are eager to join the Dutch life sciences conference - a great opportunity for high-quality networking with many start-up companies, service providers, and research organisations. This year we are happy to be showcasing our novel InnoSer Acceleration Program (ISAP)...
Novel therapeutic molecule for ADPKD presented at the ERA Congress
We look forward to connecting and learning from other life-science companies at events such as the largest annual Nephrology Congress in Europe, the ERA Congress. Study Director Nephrology Laura Blockken will attend this year’s event, which focuses on recent...
Introducing InnoSer’s acceleration program (ISAP) at Innovation for Health
Connecting with bright minds and staying at the forefront of technological developments keeps us informed on new directions and how we can integrate innovative technologies that better serve our clients. This year's Innovation for Health event will be focusing on...
The benefits of introducing Meso Scale Discovery technology to your preclinical research
Many methods to measure pharmacodynamic endpoints are currently available, for instance, enzyme-linked immunosorbent assay (ELISA), reverse transcription-polymerase chain reaction (RT-PCR), and western blotting. Measuring these endpoints is a crucial step in...